Teva's 3 Key Branded Drugs Grew Sales 33% Last Quarter. Is This Turnaround Stock a Buy Right Now?

The Motley Fool · James Halley · 2026-11-06 13:48 UTC

Teva's three branded therapies of Austedo, Ajovy, and Uzedy brought in $1.1 billion in third-quarter revenue.

Teva Pharmaceuticals (TEVA -0.17%) has increased annual revenue for three consecutive years, following a stretch in which annual revenue fell for six consecutive years.

The culprits for the Israel-based pharmaceutical company's six-year slide were increased competition from generics, pricing pressures, and the loss of exclusivity for key products. Thanks to an emphasis on higher-margin therapies, the company appears to be back on track. Its shares are up more than 34% so far this year.

The road back may still be a bumpy one. In the third quarter, revenue was $4.4 billion, down 2% year over year. However, there are plenty of positive signs.

Read the full story at The Motley Fool · All coverage of this story